601 results on '"O’Hehir, Robyn E."'
Search Results
2. Accurate determination of house dust mite sensitization in asthma and allergic rhinitis through cytometric detection of Der p 1 and Der p 2 binding on basophils (CytoBas)
3. Homologous but not heterologous COVID-19 vaccine booster elicits IgG4+ B-cells and enhanced Omicron subvariant binding
4. Combined immunodeficiency and impaired PI3K signaling in a patient with biallelic LCP2 variants
5. Current advances in house dust mite allergen immunotherapy (AIT): Routes of administration, biomarkers and molecular allergen profiling
6. IgE in allergy: It takes two
7. Allergen-Specific Immunotherapy
8. Preface
9. Contributors
10. Beyond monogenetic rare variants: tackling the low rate of genetic diagnoses in predominantly antibody deficiency
11. Collagen—An Important Fish Allergen for Improved Diagnosis
12. Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy.
13. Paradoxical Vocal Fold Motion in Difficult Asthma Is Associated with Dysfunctional Breathing and Preserved Lung Function
14. Systematic Assessment for Difficult and Severe Asthma Improves Outcomes and Halves Oral Corticosteroid Burden Independent of Monoclonal Biologic Use
15. Third dose COVID-19 mRNA vaccine enhances IgG4 isotype switching and recognition of Omicron subvariants by memory B cells after with mRNA but not adenovirus priming
16. Accurate determination of house dust mite sensitization in asthma and allergic rhinitis through cytometric detection of Der p 1 and Der p 2 binding on Basophils (CytoBas)
17. A recent patent in allergy & immunology: Biomarkers on allergen‐specific memory B cells to predict allergen immunotherapy outcome.
18. Defining specific allergens for improved component-resolved diagnosis of shrimp allergy in adults
19. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study
20. Mind the gaps: Clinical trial concepts to address unanswered questions in aeroallergen immunotherapy—An NIAID/AHRQ Workshop
21. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology
22. The changing global prevalence of asthma and atopic dermatitis
23. Trait profiles in difficult‐to‐treat asthma: Clinical impact and response to systematic assessment
24. Early increase in serum specific IgG2 upon allergen immunotherapy with a 300 IR sublingual house dust mite tablet
25. COVID-19 adenoviral vector vaccination elicits a robust memory B cell response with the capacity to recognize Omicron BA.2 and BA.5 variants
26. The second COVID‐19 mRNA vaccine dose enhances the capacity of Spike‐specific memory B cells to bind Omicron BA.2
27. Phenotypic Distinctions Between Omega-5-Gliadin Allergy and Peanut Allergy: Clinical Profile, Reaction Rates and Triggers, and Quality of Life
28. Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination
29. Peanut Allergy Biomolecular Characterization for Development of a Peanut T-Cell Epitope Peptide Therapy
30. Clinical Efficacy and Immunologic Effects of Omalizumab in Allergic Bronchopulmonary Aspergillosis
31. RNA sequencing of single allergen‐specific memory B cells after grass pollen immunotherapy: Two unique cell fates and CD29 as a biomarker for treatment effect
32. Transient acquired donor peanut allergy presenting as life-threatening anaphylaxis following lung transplantation
33. New insights into human immune memory from SARS‐CoV ‐2 infection and vaccination
34. Double-dose mRNA vaccination to SARS-CoV-2 progressively increases recognition of variants-of-concern by Spike RBD-specific memory B cells
35. Dedication
36. Preface
37. The second COVID‐19 mRNA vaccine dose enhances the capacity of Spike‐specific memory B cells to bind Omicron BA.2.
38. RNA sequencing of single allergen‐specific memory B cells after grass pollen immunotherapy: Two unique cell fates and CD29 as a biomarker for treatment effect.
39. 6 - Allergen-Specific Immunotherapy
40. Peanut oral immunotherapy: current trends in clinical trials
41. Assessment of thunderstorm-induced asthma using Google Trends
42. Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK-air (R)
43. Peptide Mediated Regulation of Allergen Specific Immune Responses
44. The dominant 55 kDa allergen of the subtropical Bahia grass (Paspalum notatum) pollen is a group 13 pollen allergen, Pas n 13
45. Ara h 2 peptides containing dominant CD4+ T-cell epitopes: Candidates for a peanut allergy therapeutic
46. Coordinated IgG2 and IgE responses as a marker of allergen immunotherapy efficacy
47. Management of anaphylaxis due to COVID‐19 vaccines in the elderly
48. Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK‐air®
49. Advances in allergen‐specific immune cell measurements for improved detection of allergic sensitization and immunotherapy responses
50. ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.